Table 3

Relative quantitation of GD2 synthase mRNA of sequential samples in the BMs of stage 4 NB patients during the course of treatment and follow-upa

TimelinePatient
12345
At diagnosis24.7 (0 m)b21.0 (0 m)107.1 (0 m)4098.3 (0 m)350.3 (0 m)
During treatment12.0 (6 m)0 (6 m)9.9 (6 m)37.4 (6 m)15.0 (1 m)
Clinical remission1.8 (12 m)0 (12 m)0 (12 m)0 (13 m)2.2 (10 m)
Follow-up4.2 (17 m)0 (18 m)0 (18 m)50.8 (17 m)8.5 (13 m)
Follow-up1.1 (24 m)0 (31 m)0 (24 m)16.2 (24 m)
Relapse25.8 (30 m)546.3 (18 m)
Relapse26.1 (41 m)
StatusPFc (73 m)PF (83 m)PF (100 m)Dead (50 m)Dead (22 m)
  • a Relative quantitation was expressed as GD2 synthase/GAPDH with a detection threshold of 5.0, as described in “Patients and Methods.”

  • b Months (m) after diagnosis.

  • c PF, progression free.